1 Repurposing FDA Approved Drugs as FXR Agonists: A Structure Based in silico Pharmacological Study Sandra Jose 1 , Sreevidya S Devi 1 , Anjana Sajeev 1 , Sosmitha Girisa 1 , Mohammed S. Alqahtani 2,3 , Mohamed Abbas 4,5 , Abdulrahman Alshammari 6 , Gautam Sethi 7,8* , Ajaikumar B. Kunnumakkara 1* 1 Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology (IIT) Guwahati, Guwahati, Assam-781039, India. 2 Radiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia. 3 BioImaging Unit, Space Research Centre, Michael Atiyah Building, University of Leicester, Leicester, LE1 7RH, U.K. 4 Electrical Engineering Department, College of Engineering, King Khalid University, Abha 61421, Saudi Arabia. 5 Computers and communications Department, College of Engineering, Delta University for Science and Technology, Gamasa 35712, Egypt. 6 Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Post Box 2455, Riyadh, 11451, Saudi Arabia. 7 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 8 NUS Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore *To whom correspondence should be addressed: Dr. Gautam Sethi, Email: phcgs@nus.edu.sg Dr. Ajaikumar B. Kunnumakkara, Email: kunnumakkara@iitg.ac.in Abstract Downloaded from http://portlandpress.com/bioscirep/article-pdf/doi/10.1042/BSR20212791/931395/bsr-2021-2791.pdf by guest on 02 April 2022 Bioscience Reports. This is an Accepted Manuscript. You are encouraged to use the Version of Record that, when published, will replace this version. The most up-to-date-version is available at https://doi.org/10.1042/BSR20212791